This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

HomeMechanism of ActionEfficacySafetyDosingHow HYMPAVZI WorksHow HYMPAVZI WorksHYMPAVZI OverviewHow HYMPAVZI WorksEfficacyEfficacyStudy DesignPrimary EndpointLong-term ProtectionSecondary EndpointsSafetySafetyAdverse EventsSafetyDosingDosingDosing OverviewMeet the HYMPAVZI PenInjection OverviewWhy HYMPAVZIWhy HYMPAVZIAddresing Patient NeedsWhy HYMPAVZIResourcesResourcesMaterialsVideos

Click here for HYMPAVZI®▼ (marstacimab) Prescribing Information.

Prefilled fixed dose pen. Once-weekly dosing1Dosing schedule
 The recommended dose of HYMPAVZI for patients 12 years of age and older weighing ≥35 kg is an initial loading dose of 300 mg by subcutaneous injection followed thereafter by 150 mg by subcutaneous injection once weekly, at any time of day.1

*Once reaching room temperature, HYMPAVZI should not be returned to refrigerated storage. Keep the HYMPAVZI pen in its original carton to protect from light.1 For full instructions, please consult the Instructions for UseDose escalationIf control of bleeding events is deemed inadequate by a healthcare professional, consider adjusting weekly dose to 300 mg subcutaneous injection in patients weighing ≥50 kg. Do not exceed maximum weekly dose of 300 mg.1Switching to HYMPAVZI

• If switching from a prophylactic factor replacement therapy, patients should discontinue treatment with clotting factor concentrates (FVIII or FIX), and then initiate HYMPAVZI at any time afterwards1
• No clinical study data are currently available to guide switching patients from non-factor-
based haemophilia medicinal products1

Please consult the Summary of Product Characteristics for more information on dosing and switching to HYMPAVZI, and guidance on management in the perioperative setting.

HYMPAVZI is intended for use under the guidance of a healthcare professional. After proper training in subcutaneous injection technique, a patient may self-inject, or the patient’s caregiver may administer HYMPAVZI, if a healthcare professional determines that it is appropriate.1

FIX, factor IX; FVIII, factor VIII

References:

1. HYMPAVZI (marstacimab). Summary of Product Characteristics
PP-HYM-GBR-0102. June 2025
HYMPAVZI Instructions for Use

Watch this video to learn about how HYMPAVZI can be administered.

Watch nowHow does HYMPAVZI work?

HYMPAVZI is a human monoclonal antibody.1Learn more about anti-TFPI and how HYMPAVZI works within the clotting cascade.

Mechanism of ActionLoading

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2025 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-11245. January 2025
You are now leaving PfizerPro​​​​​
​
You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-GBR-12070. April 2025​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024.

YesNo
You are now leaving PfizerPro

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer's medicines or business which it has provided or reviewed.

PP-UNP-GBR-12107. April 2025
​​​​​​​